Evidence for NK-1 receptor subtypes from in vivo bronchopulmonary and cardiovascular studies.
Floch
A
A
Rhone-Poulenc Rorer, CRVA, Vitry-sur-Seine, France.
Massa
N
N
Thiry
C
C
Cavero
I
I
D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D001980:Bronchi / Q000187:drug effects / Q000502:physiology*; D016084:Bronchoconstriction / Q000187:drug effects*; D006168:Guinea Pigs; D007211:Indoles / Q000494:pharmacology*; D054833:Isoindoles; D008168:Lung / Q000187:drug effects / Q000502:physiology*; D008297:Male; D015288:Neurokinin A / Q000502:physiology; D064729:Neurokinin-1 Receptor Antagonists; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000502:physiology*; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors / Q000502:physiology*; D013373:Substance P / Q000037:antagonists & inhibitors*
D001713:Biphenyl Compounds; D007211:Indoles; D054833:Isoindoles; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; D013373:Substance P; D015288:Neurokinin A; C066892:CP 96345